Advertisement

Topics

RXi Pharma selects two sd─rxRNA compounds from immuno─oncology pipeline for preclinical development

09:24 EDT 9 Aug 2017 | PharmaBiz

RXi Pharmaceuticals Corporation, a clinical─stage RNAi company developing innovative therapeutics that address significant unmet medical needs, has selected two self─delivering RNAi (sd─rxRNA) compounds from its immuno─oncology pipeline for preclinical development.

Original Article: RXi Pharma selects two sd─rxRNA compounds from immuno─oncology pipeline for preclinical development

NEXT ARTICLE

More From BioPortfolio on "RXi Pharma selects two sd─rxRNA compounds from immuno─oncology pipeline for preclinical development"

Quick Search
Advertisement
 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...